Evalution the Safety and Efficacy in Atopic Dermatitis Patients

Kangstem Biotech

Status: Unknown

Conditions: Atopic Dermatitis

Treatments: Other: Not applicable(observational study)

Study type: Observational

Funder types: Industry

Identifiers

NCT03962387

K0102-E

Details and patient eligibility

About

A multi-center, open, long-term follow-up study to evaluate the efficacy and safety of FURESTEM-AD inj. in patients with moderate to severe chronic atopic dermatitis: 5-year results from the K0102 extension study

Enrollment: 98 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subject who enrolled K0102 Clinical Trial(parent study).
2. Subjects who understand and voluntarily sign an informed consent form

Exclusion criteria

1. In case follow-up is not possible from end of K0102 clinical trial to end of this study period
2. Any other condition which the investigator judges would make patient unsuitable for study participation

Trial design

98 participants in 1 patient group

Atopic Dermatitis

Treatment:

Other: Not applicable(observational study)